EAST RUTHERFORD, N.J., Aug. 30, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that company management will present at the following investor conferences in September:
2017 Wells Fargo Healthcare Conference
Date: Wednesday, September 6, 2017
Time: 4:10 p.m. EDT
Location: Boston, MA
Baird’s 2017 Global Healthcare Conference
Date: Thursday, September 7, 2017
Time: 10:15 a.m. EDT
Location: New York, NY
The live audio webcasts and slide presentations can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and replays will be available for 90 days after the live events conclude.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura Investor Relations Associate Tel: 201.804.3037 Email: [email protected]


FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Italy Fines Apple €98.6 Million Over App Store Dominance
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 



